MedTrace Logo

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

NCT03059797 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-05-16

No results posted yet for this study

Summary

To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).

Conditions

Interventions

DRUG

Anlotinib

Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle

DRUG

Placebo

Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2018-06-30
Completion
2019-05-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03059797 on ClinicalTrials.gov